Publication Name	World Journal of Gastroenterology
Manuscript ID	4332
Country	Spain

Received	2013-06-27 12:06
Peer-Review Started	2013-06-27 17:43
To Make the First Decision	2013-07-19 08:39
Return for Revision	2013-07-20 13:37
Revised	2013-08-07 15:43
Second Decision	2013-09-29 10:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-09-29 21:56
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-10-14 23:46
Typeset the Manuscript	2013-11-07 10:38
Publish the Manuscript Online	2013-11-18 10:59

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver
Manuscript Source	Invited Manuscript
All Author List	María Rojas-Feria, Manuel Castro, Emilio Suárez, Javier Ampuero and Manuel Romero-Gómez
Funding Agency and Grant Number
Corresponding Author	Manuel Romero-Gómez, MD, PhD, Professor of Medicine, Unit for Medical and Surgical Management of Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Avda. Bellavista s/n, E-41014 Sevilla, Spain. mromerogomez@us.es
Key Words	Inflammatory bowel disease; Hepatobiliary disorders; Extraintestinal manifestations; Primary sclerosing cholangitis; Drug-induced liver injury; Hepatotoxicity; Hepatitis B; Hepatitis C
Core Tip	Hepatobiliary disorders are common extraintestinal manifestations of inflammatory bowel disease (IBD) that become a diagnostic challenge for the gastroenterologist. In this review, we have summarized the main diseases involving the hepatobiliary system in IBD and secondary liver toxicity to IBD treatment. This review also highlights the impact of immunosuppressive and anti-tumor necrosis factor treatment in hepatitis B and C, as well as its prophylaxis and treatment, according to current clinical practice guidelines.
Publish Date	2013-11-18 10:59
Citation	Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. World J Gastroenterol 2013; 19(42): 7327-7340
URL	http://www.wjgnet.com/1007-9327/full/v19/i42/7327.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i42.7327

Full Article (PDF)	WJG-19-7327.pdf
Manuscript File	4332-Review.doc
Answering Reviewers	4332-Answering reviewers.pdf
Copyright License Agreement	4332-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4332-Language certificate.pdf
Peer-review Report	4332-Peer review(s).pdf
Scientific Editor Work List	4332-Scientific editor work list.doc